learn2.peerview.com Open in urlscan Pro
2606:4700::6812:1549  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THIS CONTENT WAS DESIGNED FOR
PORTRAIT ORIENTATION ONLY.



   
 * Get Credit


CME/MOC/NCPD/CPE Information Get Credit Practice Aids SlidesPodcastsAbbr.Share
Feedback
1.0 CME/MOC/NCPD/CPEThis activity expired on November 25, 2022; credit is no
longer available.
Exploring the Convergence of Advances in S1P Receptor Modulation With Progress
in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Chair & Presenter
Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California
Presenter
Lauren B. Krupp, MD
NYU Grossman School of Medicine
MS Comprehensive Care Center
NYU Langone Health
New York, New York
Chapter ContentActivity Chapters

Please complete and tap Submit at the end to continue.

Question 1/4
Which of the following therapies has high affinity binding for the S1P3
receptor?
   
   
 * I’m not sure
   
   
   
 * Siponimod
   
   
   
 * Fingolimod
   
   
   
 * Ozanimod
   
   
   
 * Ponesimod
   
   
   
 * Fingolimod and siponimod
   
   
   
 * Fingolimod, siponimod, ozanimod, and ponesimod
   
   
   
 * N/A for me
   
   

Question 2/4
What statement represents your current view on the role of S1P receptor
modulator therapy for the management of multiple sclerosis in a newly diagnosed,
treatment-naïve patient?
   
   
 * I’m unsure of the role of S1P receptor modulators in this clinical context
   
   
   
 * S1P receptor modulators are reasonable options for first-line therapy
   
   
   
 * S1P receptor modulators are appropriate for first-line therapy only and do
   not have a role in subsequent lines of treatment
   
   
   
 * S1P receptor modulators should be reserved for second- or third-line therapy
   
   
   
 * N/A for me
   
   

Question 3/4
How familiar are you with cognitive assessments that are used to screen for
cognitive impairment in MS?
   
   
 * Not at all familiar
   
   
   
 * Slightly familiar
   
   
   
 * Somewhat familiar
   
   
   
 * Moderately familiar
   
   
   
 * Extremely familiar
   
   
   
 * N/A for me
   
   

Question 4/4
How familiar are you with existing data on the effects of S1PR modulators on
cognition?
   
   
 * Not at all familiar
   
   
   
 * Slightly familiar
   
   
   
 * Somewhat familiar
   
   
   
 * Moderately familiar
   
   
   
 * Extremely familiar
   
   
   
 * N/A for me
   
   

Submit


ACTIVITY CHAPTERS

PRE-TEST


Seminar 1: Recognizing the Rationale Behind S1P Receptor Modulation for MS
Management

LONG-TERM BENEFITS OF EARLY INITIATION OF HIGH-EFFICACY THERAPY - 1:53



MOA, THERAPEUTIC TARGETS, AND RECEPTOR SPECIFICITY - 4:45



EFFICACY AND SAFETY DATA - 4:43



PRACTICAL ASPECTS OF USE - 2:25



SUSTAINED THERAPEUTIC EFFECTS AND THE BENEFITS OF SWITCHING - 1:38


Seminar 2: What Novel Disease Markers May Reveal About the Impact of S1PR
Modulators on MS

PRESENTATION, CHARACTERIZATION, AND BURDEN OF COGNITIVE IMPAIRMENT - 5:44



SCREENING FOR COGNITIVE IMPAIRMENT - 2:35



MANAGEMENT OF COGNITIVE IMPAIRMENT: NONPHARMACOLOGIC INTERVENTIONS - 2:00



IMPACT OF DISEASE MODIFYING THERAPIES AND PREDICTIVE BIOMARKERS ON COGNITION -
1:37



S1PR MODULATORS: EFFECTS ON IMAGING AND MOLECULAR BIOMARKERS OF DISEASE
PROGRESSION - 3:37



S1PR MODULATORS: EFFECTS ON COGNITIVE TEST SCORES - 5:22


Case Workshop: S1PR Modulators in Personalized MS Management

PATIENT AVB - 6:15



REVISITING PATIENT AVB - 8:47



Q&A - 2:18



KEY TAKEAWAYS - 2:26



GET CREDIT




SEE MORE EDUCATION FROM PEERVIEW IN NEUROLOGY


CONNECT WITH US




Copyright © 2000-2021, PeerView
Terms of Use | Privacy Policy | Sign Up for Email Alerts


This site uses cookies.Learn More.
×